MD Anderson Researchers: When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs

According to Mien-Chie Hung, Ph.D., professor and chair of University of Texas MD Anderson’s Department of Molecular and Cellular Oncology in Houston, tumor cells are often exposed to low oxygen levels (hypoxia) which in turn causes the epidermal growth factor receptor (EGFR) to send signals that interfere with miRNA processing thus promoting cancer.

http://bionews-tx.com/news/2013/05/28/md-anderson-researchers-when-oxygen-is-short-egfr-prevents-maturation-of-cancer-fighting-mirnas/

Marina Biotech Licensee Mirna Therapeutics Reports Initiation of CPRIT-Funded Phase 1 Clinical Trial of Anticancer Drug MRX34

Marina Biotech, well known for its developmental and innovative projects dealing with nucleic acid-based drugs, has announced the initiation of phase 1 clinical trials of MRX34 by its licensee, Mirna Therapeutics.

http://bionews-tx.com/news/2013/05/15/marina-biotech-licensee-mirna-therapeutics-reports-initiation-of-cprit-funded-phase-1-clinical-trial-of-anticancer-drug-mrx34/

Mirna Therapeutics First to Advance MicroRNA Into Cancer Clinic Treatment

A leading Texas biotechnology company, Mirna Therapeutics, Inc. has announced the initiation of Phase 1 clinical trials of MRX34 in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.

http://bionews-tx.com/news/2013/05/15/mirna-therapeutics-is-first-to-advance-microrna-into-the-clinic-for-cancer/

Austin, Texas Biotech Company Mirna Thereaputics To Present Preclinical Data For Cancer Treatment At Keystone Conference

Mirna Theraputics, an innovative Texas biotech company in Austin, Texas, will present data to suggest that its new lead product MRX34 is an effective means of tumor suppression.

http://www.swbiosearch.com/2013/01/23/austin-texas-biotech-company-mirna-thereaputics-to-present-preclinical-data-for-cancer-treatment-at-keystone-conference/